Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | cation channel family protein | 0.0188 | 0.8608 | 0.8571 |
Echinococcus multilocularis | ryanodine receptor 44f | 0.0088 | 0.1416 | 0.1416 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0072 | 0.026 | 0.5 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0207 | 1 | 1 |
Trypanosoma brucei | inositol 1,4,5-trisphosphate receptor | 0.0103 | 0.2549 | 0.235 |
Loa Loa (eye worm) | hypothetical protein | 0.0119 | 0.3703 | 0.2664 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0207 | 1 | 1 |
Schistosoma mansoni | ryanodine receptor related | 0.0123 | 0.3934 | 0.3772 |
Brugia malayi | Ryanodine Receptor TM 4-6 family protein | 0.0123 | 0.3934 | 0.3772 |
Leishmania major | 2-oxoglutarate dehydrogenase, e3 component, lipoamidedehydrogenase-like protein | 0.0072 | 0.026 | 0.0099 |
Echinococcus multilocularis | dihydrolipoamide dehydrogenase | 0.0072 | 0.026 | 0.026 |
Treponema pallidum | NADH oxidase | 0.0072 | 0.026 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0117 | 0.354 | 0.2475 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0072 | 0.026 | 0.5 |
Echinococcus granulosus | dihydrolipoamide dehydrogenase | 0.0072 | 0.026 | 0.026 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0072 | 0.026 | 0.5 |
Loa Loa (eye worm) | glutathione reductase | 0.0207 | 1 | 1 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0072 | 0.026 | 0.5 |
Leishmania major | dihydrolipoamide dehydrogenase, putative | 0.0072 | 0.026 | 0.0099 |
Plasmodium vivax | glutathione reductase, putative | 0.0207 | 1 | 1 |
Schistosoma mansoni | inositol 145-trisphosphate receptor | 0.0153 | 0.609 | 0.5985 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0207 | 1 | 1 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0207 | 1 | 1 |
Brugia malayi | Thioredoxin reductase | 0.0207 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.01 | 0.2287 | 0.1015 |
Leishmania major | trypanothione reductase | 0.0207 | 1 | 1 |
Trypanosoma brucei | trypanothione reductase | 0.0207 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0072 | 0.026 | 0.5 |
Leishmania major | acetoin dehydrogenase e3 component-like protein | 0.0072 | 0.026 | 0.0099 |
Plasmodium falciparum | glutathione reductase | 0.0207 | 1 | 1 |
Trypanosoma cruzi | inositol 1,4,5-trisphosphate receptor, putative | 0.0103 | 0.2549 | 0.235 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0072 | 0.026 | 0.5 |
Toxoplasma gondii | thioredoxin reductase | 0.0207 | 1 | 1 |
Plasmodium falciparum | thioredoxin reductase | 0.0207 | 1 | 1 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0207 | 1 | 1 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0207 | 1 | 1 |
Echinococcus granulosus | ryanodine receptor 44f | 0.0088 | 0.1416 | 0.1416 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0072 | 0.026 | 0.5 |
Leishmania major | dihydrolipoamide dehydrogenase, putative | 0.0072 | 0.026 | 0.0099 |
Schistosoma mansoni | inositol 145-trisphosphate receptor | 0.01 | 0.2287 | 0.2081 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0072 | 0.026 | 0.5 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0072 | 0.026 | 0.5 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0072 | 0.026 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED20 (functional) | = 0.024 mM kg-1 | Hypoglycemic activity by lowering blood glucose in normal rats by 20% after oral administration. | ChEMBL. | 6864736 |
ED50 (functional) | = 0.062 mM kg-1 | Hypoglycemic activity by lowering blood glucose in normal rats by 50% after oral administration. | ChEMBL. | 6864736 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.